Peter Martin

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

Michael Wang, Simon Rule, Peter Martin et al. · New England Journal of Medicine · 2013 · 1.7K citations · Full text

PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma

Ajay K. Gopal, Brad S. Kahl, Sven de Vos et al. · New England Journal of Medicine · 2014 · 1K citations · Full text

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results

Michael Wang, Kristie A. Blum, Peter Martin et al. · Blood · 2015 · 396 citations · Full text

Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma

Peter Martin, Amy Chadburn, Paul J. Christos et al. · Journal of Clinical Oncology · 2009 · 335 citations

Bortezomib Plus CHOP-Rituximab for Previously Untreated Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma

Jia Ruan, Peter Martin, Richard R. Furman et al. · Journal of Clinical Oncology · 2010 · 317 citations · Full text